In PRAD, LCN2 expression was positively correlated with expression of CD244, CD48, LGALS9, TNFSF14, TMIGD2, VTCN1, TNFSF9, TNFRSF8, CD27, TNFRSF25, VSIR, TNFRSF4, CD40, TNFRSF15, CD86, and CD44 (Figure 5A). Here, LGALS9 is linked to prostate adenocarcinoma.